Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

BACKGROUND: Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments’ value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lauro, V., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Del Mastro, L., Giuliano, M., Puglisi, F., De Laurentiis, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808450/
https://www.ncbi.nlm.nih.gov/pubmed/36399953
http://dx.doi.org/10.1016/j.esmoop.2022.100629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808450/
https://www.ncbi.nlm.nih.gov/pubmed/36399953
http://dx.doi.org/10.1016/j.esmoop.2022.100629

Ejemplares similares